Proteomics flags US rollout of kidney test at global diabetes summit
ASX-listed diagnostics disruptor Proteomics International has officially launched its innovative kidney disease test, PromarkerD, in the massive United States healthcare market.
The launch took place at the American Diabetes Association's 85th scientific sessions talkfest in Chicago. The annual conference marks the world's largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market.
PromarkerD is a simple predictive blood test capable of identifying a person's risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes.
According to clinical studies, the patented test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms.
'This marks a significant milestone in our global commercialisation strategy.'
Proteomics International managing director Dr Richard Lipscombe
More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget.
Proteomics International managing director Dr Richard Lipscombe said: 'We're excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.'
The PromarkerD rollout will begin in California, supported by the company's recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International's integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement.
Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test 'a paradigm shift in diabetes care.' Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Courier-Mail
5 hours ago
- Courier-Mail
Scientists may have discovered a cure for baldness – but there's a catch
1/5 Researchers at San Carlos Clinical Hospital in Madrid have developed a cure for androgenetic alopecia, commonly known as pattern hair loss. An estimated 80 million Americans – 50 million men and 30 million women – experience some form of alopecia, although it affects women differently than men. Men usually go through a receding hairline and bald spots, whereas women get thinner at the part line but rarely go fully bald. In the study – published in the journal Stem Cell Research and Therapy – researchers used a combo of fat‑tissue-derived stem cells and the energy molecule ATP to reverse hair loss in mice, with shocking results.
West Australian
6 hours ago
- West Australian
ASX Runners of the Week: Amplia, archTIS and Vanadium Resources
If you were looking for correlation between the seemingly continuous breakouts of military hostilities between nuclear-armed nations and the market - good luck. The ASX continued at near all-time highs this week, pulling back a fraction by Friday, as conflict between Iran and Israel continued to rise. The oil price surged a further 10 per cent this week as Israel turned its focus from Iran's nuclear facilities to targeting its oil and gas infrastructure. Uranium stocks were the week's main winners. Surprisingly, they were not fuelled directly by global drivers, but rather by investment heavyweight Sprott's physical uranium trust purchase of $200 million worth of uranium oxide, which was announced on Monday. The result for uranium stocks on the index was deafening. Uranium miners Boss Energy, Paladin Energy and Deep Yellow were among the most heavily shorted on the ASX, making up three of the top 10 shorted companies. A sharp increase in uranium caused a two-fold effect of en masse buying and short seller panic to close out positions, with the big three uranium stocks all surging up 20 per cent on the day. In a rare shake-up, no Australian-based resource companies feature on this week's Bulls N' Bears' ASX Runners list. Instead, the chocolates went to a groundbreaking Aussie biotech story, which could be on to the makings of one of the biggest breakthroughs in oncology treatment in years. AMPLIA THERAPEUTICS (ASX: ATX) Up 339% (5.7c – 25c) This week's Bulls N' Bears ASX Runner of the Week is biotech trailblazer Amplia Therapeutics, which sent the market into an absolute tailspin thanks to a jaw-dropping set of results from a clinical trial for incredibly nasty pancreatic cancer. On Monday, the company announced a pathological complete response – no detectable signs of cancer - in a patient enrolled in its ACCENT trial of a drug therapy to limit tumour growth. The trial combined the therapy narmafotinib with two other drugs to treat a patient with metastatic (stage IV) pancreatic cancer. After surgery, the patient's primary and metastatic tumours showed no live cancer cells, a unicorn-rare outcome in this brutal disease, where no detectable cancer signs are less common than a sunny day in Melbourne. The market mumbled and murmured through Wednesday, then stacked 42 per cent onto Amplia's share price. Thursday brought a different tune: a second patient, out of 55 enrolled in the trial, achieved a confirmed complete response, with all tumour lesions vanishing for more than two months. In advanced pancreatic cancer, where one complete response in 431 patients is headline-worthy, two in a trial appears groundbreaking. The market lost its collective marbles and the company's shares rocketed to 25 cents per share – up 339 per cent - on Friday with more than $30 million in shares traded on the week. The move also delivered a handy little profit for Amplia's second largest shareholder Acorn Capital, which picked up a further $350,000 worth of shares on Monday, when it saw value before the broader market. Pancreatic cancer is Australia's eighth most common cancer and has a dismal 12.5 per cent five-year survival rate. With United States Food and Drug Administration registration already in the bag, Amplia's drug looks to be on the charge to transform oncology, especially as healthcare systems globally grapple with rising cancer burdens and demand for precision therapies. ARCHTIS LTD (ASX: AR9) Up 287% (6.2c – 24c) Taking out silver on this week's Runners list is cybersecurity expert archTIS Limited, which saw its share price catapult 390 per cent by Wednesday, before the ASX killjoys slammed it into suspension, ending any hopes the company could take out the coveted Bulls N' Bears podium. The company released a duo of blockbuster defence contracts on Monday and Wednesday, before archTIS' management rubbed shoulders with some of the world's cybersecurity elite. On Monday, the company unveiled a US Defence Department contract for 1000 licences for its NC Protect data security software, worth $38,500 a pop for six months, to lock down sensitive data in Microsoft's DoD365 cloud. After months of brutal testing by the prime global contractor, NC Protect came up trumps as the only integrated solution for robust, scalable attribute-based access control. ArchTIS says its product could address a potential 150,000-user rollout across the warfighter network, if it proves a success for the defence department. Amazingly, $100,000 worth of shares traded on Monday, before going supersonic on Tuesday, to push the company's share price up 100 per cent from last week's close on $600,000 shares traded. ArchTIS dropped a second bomb on Wednesday, announcing a three-year $263,185 deal for 400 users with a United Kingdom-based aerospace and defence titan, which is poised to be a blueprint for more than 100,000 potential users in a global Microsoft 365 rollout. The company's share price hit a peak of 24c for a gain of 287 per cent this week, on $1.4 million in intraday trading, before the compliance overlords at the ASX cried 'disorderly market' and placed the company into suspension, where it remains. It's likely a few day traders were caught flat-footed by the suspension and were no doubt scouring around to come up with the cash to settle on trades they had hoped to flip by market close on Wednesday. In a world where cyberattacks are spiking, archTIS' NC Protect could fulfil a crucial defence need. Its ability to secure sensitive communications in cloud environments, such as the DoD365 and Microsoft 365 platforms, is critical as nations race to shield their military and industrial data from state-sponsored threats. With geopolitical tensions boiling and the US and UK doubling down on cybersecurity to protect their defence industrial bases, archTIS' tech is perfectly timed to cash in on the global push for ironclad digital fortresses, making it a potential darling in the market and of Western military alliances. VANADIUM RESOURCES LTD (ASX: VR8) Up 185% (1.3c – 3.7c) Snagging the final spot on the Runners of the Week podium is the aptly named critical minerals developer Vanadium Resources, which shot out of a cannon on Tuesday, after inking a non-binding memorandum of understanding (MoU) with China Precious Asia (CPA). Vanadium will supply 1.2 million tonnes per annum of vanadium-rich magnetite direct shipping ore to the heavyweight global metals trader from its world-class Steelpoortdrift vanadium project in South Africa. The MoU positions Vanadium to tap into early cash flows at the fully permitted Steelpoortdrift, a behemoth resource with 680 million tonnes of ore at 0.70 per cent vanadium oxide, which is equivalent to 4.74Mt contained vanadium. That rate is enough to keep the company's lights on for more than 180 years. CPA will handle loading and collection of the direct shipping ore, with Vanadium retaining a nimble ±25 per cent supply flexibility each month, kicking off by December this year. Management believes the material positive operating cash flows will fast track its development, with good reason. Steelpoortdrift's vanadium-rich ore also brims with iron-rich magnetite, making it a dual-treat commodity in the Asian steel market. The news sent the company's long-beleaguered share price soaring a cheeky 185 per cent from last Friday's 1.3c close to a 3.7c peak on $230,000 in stock traded. Vanadium is also actively sniffing out profit-share deals and acquisitions to bolster its near-term game plan without derailing the direct shipping ore opportunity. The deal looks beneficial for both parties as vanadium supplies are projected to be in global deficit this year, coupled with China's ambitions to diversify from its dependence on Australian-based iron ore. Steelpoortdrift's high-grade, low-cost direct shipping option has reignited global and now market interest in the company. If Vanadium can lock in a binding agreement with CPA, this plucky minnow could vault into the vanadium big league and potentially self-fund its own mine development. Is your ASX-listed company doing something interesting? Contact:
News.com.au
8 hours ago
- News.com.au
Scott Power: ASX health stocks fall in ‘lacklustre week'
ASX heath sector falls 1.1% over past five days The US FDA approves CSL's Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. The ASX healthcare sector has had what Morgans' senior healthcare analyst Scott Power described as a "lacklustre week". At lunchtime on Friday, the S&P/ASX 200 Health Care index (ASX:XHJ) was down 1.1% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) fell 0.55% for the same period. Markets have been influenced by global economic and geopolitical concerns, particularly escalating tensions between Iran and Israel. And it seems US President Donald Trump has not backed down from tariffs on pharmaceutical imports. A United States Department of Commerce investigation is underway under Section 232 of the Trade Expansion Act of 1962 – a provision that allows the president to restrict imports if they are deemed a threat to national security. Returning from the G7 Summit in Canada Trump reportedly told media on Air Force One tariffs on the sector were coming. "We're going to be doing pharmaceuticals very soon," he said. "That's going to bring all the companies back into America... at least partially back in." Power said Trump's latest comments were adding further jitters to the sector. "Until we get clarity there's going to be volatility," he said. Power's Powerplay – CSL gets FDA approval for Andembry The ASX's largest healthcare stock CSL (ASX:CSL) has notched a milestone with the FDA approving its Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE). Affecting about one in 50,000 people CSL said HAE was the first and only treatment targeting factor XIIa for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older. The approval was based on a pivotal phase III (VANGUARD) trial and ongoing open-label extension study, showing Andembry reduced the median number of HAE attacks by more than 99% (mean 89.2%), compared to placebo. Andembry is also the only treatment to offer once-monthly dosing from the start for all patients and is administered via an autoinjector. The drug is already available in Australia, the UK, EU, Japan, Switzerland and UAE. CSL said Andembry will be launched "immediately", with availability through third-party specialty pharmacy network before the end of June. In a note to clients, Morgans' healthcare analyst Derek Jellinek wrote that while Andembry's US approval had taken longer than expected, with application filing in December '24, it's good to see the drug greenlit before the end of '25 "despite the ongoing tumultuous environment" at the US Food and Drug Administration at the agency. "We view Andembry's unique MOA (ie upstream inhibition of key pathways leading to HAE attacks, so broader applicability), favourable safety profile and convenient dosing (every 4 weeks via subcutaneous injection) as key differentiators," Jellinek wrote. While Andembry is expected to impact Berinert sales – CSL's treatment for acute HAE attacks – Jellinek believes the effect should be modest. He wrote Berinert's revenue was forecast to remain steady in FY25 at US$242 million, accounting for less than 2% of CSL's total revenue. Sales are projected to ease slightly to US$230m in FY26 and US$225 million in FY27. However, this is more than compensated by anticipated growth in Andembry sales, which are expected to reach US$120m in FY26 and increase to US$220m in FY27. Morgans has an add rating on CSL and 12-month target price of $329.26. Clever Culture Systems delivers clever Q3 FY25 result Clever Culture Systems (ASX:CC5) has achieved its second consecutive quarter of positive cashflow operations with $500,000 net cash inflow in Q3 FY25 and is on track to achieve break-even or better for H2 FY25. During the quarter Clever Culture continued to execute on its commercialisation strategy for its APAS Independence instruments in the pharmaceutical market, building on success with big pharma companies Astra Zeneca and Bristol Myers Squibb (BMS). The instruments use artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. Since launching the product in March 2024, Clever Culture said it had completed sales and received orders from pharmaceutical customers for 13 APAS instruments, representing ~$6 million in revenue with a pipeline of 40 qualified opportunities. Clever Culture finished Q3 FY25 with a cash position of $2.2m. "Other top 10 pharmaceutical companies are expected to engage with CC5 following the AstraZeneca and Bristol Myers Squibb success," Power said. Emvision awarded $5 million government grant EMVision Medical Devices (ASX:EMV) has been awarded a $5 million federal government grant to further development of its First Responder portable brain scanner. The funds are by way of an Australian government Industry Growth Program (IGP) Commercialisation and Growth Grant. First Responder is EMVision's second product and distinguishes between bleed and clot strokes at the scene and is designed to be used by ambulances and by paramedics. The device should shorten diagnosis time, a crucial element in the patient getting the right treatment. EMVision's first commercial device – the emu bedside brain scanner – is also designed to rapidly diagnose stroke at the point-of-care with a pivotal trial underway to supports US Food and Drug Administration (FDA) de novo (new device) clearance. Audeara hits record, Micro-X gets milestone payment boost In other news of the week, specialist in listening solutions for people with hearing challenges Audeara (ASX:AUA) has delivered record revenue exceeding $3.64 million for the 11 months to end of May FY25. Audeara reported revenue for the 11-month period was up 14% on FY24 total revenue and 25% on FY23, which the company said signalled underlying strength of its ongoing operations. The company expects additional growth to materialise in coming weeks based on strong June 2025 trading. And leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) has received $2.3 million in milestone payments for two projects. MicroX achieved milestone three under its development agreement with US Advanced Research Projects Agency for Health (ARPA-H) and Department of Homeland Security (DHS) for a full body CT scanner, delivering $1.4 million. The company also achieved milestone two under a strategic partnership deal with Billion Prima for a baggage and parcel scanning unit due for completion in 2025, delivering $900,000. "We are pleased to continue to deliver strong progress on these key development contracts with ARPA-H, DHS, and Billion Prima respectively, which is a testament to our focus and timely delivery on key projects," Micro-X CEO Kingsley Hall said. "We are also well advanced with the final stages of our Head CT development as we prepare to enter human imaging trials." The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Clever Culture Systems, Audeara and EMVision are Stockhead advertisers, the companies did not sponsor this article.
